Relationship of Transforming Growth Factor-βl and Arginase-1 Levels with Long-term Survival after Kidney Transplantation

Abstract

In this study, we compared the serum levels of transforming growth factor-pi (TGF-β1), interleukin-10 (IL-10), and arginase-1 in long-term survival kidney transplant recipients (LTSKTRs) with those in short-term survival kidney transplant recipients (STSKTRs). We then evaluated the relationship between these levels and graft function. Blood samples were collected from 50 adult LTSKTRs and 20 STSKTRs (graft survival approximately 1–3 years post-transplantation). All patients had stable kidney function. The samples were collected at our institution during the patients' follow-up examinations between March 2017 and September 2017. The plasma levels of TGF-β1, IL-10, and arginase-1 were analyzed using enzyme-linked immunosorbent assays (ELIS A). The levels of TGF-β1 and arginase-1 were significantly higher in the LTSKTRs than in the STSKTRs. The time elapsed since transplantation was positively correlated with the levels of TGF-β1 and arginase-1 in the LTSKTRs. The estimated glomerular filtration rate was positively correlated with the TGF-β1 level, and the serum creatinine level was negatively correlated with the TGF-β1 level. Higher serum levels of TGF-pi and arginase-1 were found in LTSKTRs than in STSKTRs, and we found that TGF-β1 was positively correlated with long-term graft survival and function. Additionally, TGF-β1 and arginase-1 levels were positively correlated with the time elapsed since transplantation. On the basis of these findings, TGF-β1 and arginase-1 may play important roles in determining long-term graft survival. Thus, we propose that TGF-pi and arginase-1 may potentially be used as predictive markers for evaluating long-term graft survival.

Keywords

transforming growth factor β1 / arginase-1 / long-term survival kidney transplant recipients / estimated glomerular filtration rates / serum creatinine

References

[1] SolaE, Gonzalez-MolinaM, CabelloM, et al.. Longterm improvement of deceased donor renal allograft survival since 1996: a single transplant center study. Transplantation, 2010, 89(6): 714-720

[2] WekerleT, SegevD, LechlerR, et al.. Strategies for long-term preservation of kidney graft function. Lancet, 2017, 389(10084): 2152-2162

[3] NankivellBJ, KuypersDR. Diagnosis and prevention of chronic kidney allograft loss. Lancet, 2011, 378(9800): 1428-1437

[4] LambKE, LodhiS, Meier-KriescheHU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant, 2011, ll(3): 450-462

[5] DantalJ, HourmantM, CantarovichD, et al.. Effect of long-term immunosuppression in kidneygraft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet, 1998, 351(9103): 623-628

[6] LegendreC, CanaudG, MartinezF. Factors influencing long-term outcome after kidney transplantation. Transpl Int, 2014, 27(1): 19-27

[7] ColakH, ErsanS, TanrisevM, et al.. Relationship of Interleukin-10 and Transforming Growth Factorbeta Levels With Short-Term Graft Function After Kidney Transplantation. Transplant Proc, 2015, 47(5): 1360-1363

[8] LuanY, MosheirE, MenonMC, et al.. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion. Am J Transplant, 2013, 13(12): 3123-3131

[9] LeesJR, AzimzadehAM, BrombergJS. Myeloid derived suppressor cells in transplantation. Curr Opin Immunol, 2011, 23(5): 692-697

[10] LeveyAS, StevensLA, SchmidCH, et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009, 150(9): 604-612

[11] HallerM, GutjahrG, KramarR, et al.. Costeffectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant, 2011, 26(9): 2988-2995

[12] Pediatr Transplant, 2017, 21(2):

[13] KrystufkovaE, SekerkovaA, StrizI, et al.. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant, 2012, 27(6): 2576-2582

[14] TaamsL, Vukmanovic-StejicM, SalmonM, et al.. Immune regulation by CD4+CD25+ regulatory T cells: implications for transplantation tolerance. Transpl Immunol, 2003, 11(3-4): 277-285

[15] ScaleaJR, TomitaY, LindholmCR, et al.. Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms. Front Immunol, 2016, 7: 87

[16] LiuL, DengS, TengL, et al.. Absolute of CD4(+) CD25(+)FOXP3(+) regulatory T-cell count rather than its ratio in peripheral blood is related to longterm survival of renal allografts. Transplant Proc, 2012, 44(1): 284-286

[17] AkdisM, BlaserK, AkdisCA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol, 2005, 116(5): 961-968

[18] ShevachEM, McHughRS, PiccirilloC A, et al.. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunological reviews, 2001, 182: 58-67

[19] LloydCM, HawrylowiczCM. Regulatory T cells in asthma. Immunity, 2009, 31(3): 438-449

[20] Garcia-CovarrubiasL, VenturaE, SotoV, et al.. Lack of Association Between Elevated Urinary Levels of Interleukin-10 and Interferon Gamma With the Presence of Inflammation in Kidney Transplant Recipients. Transplant Proc, 2016, 48(2): 583-587

[21] GretenTF, MannsMP, KorangyF. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol, 2011, 11(7): 802-807

[22] BorosP, OchandoJC, ChenSH, et al.. Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol, 2010, 71(11): 1061-1066

[23] DuranteW, JohnsonFK, JohnsonRA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol, 2007, 34(9): 906-911

[24] RodriguezPC, QuicenoDG, ZabaletaJ, et al.. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res, 2004, 64(16): 5839-5849

[25] RodriguezPC, ZeaAH, DeSalvoJ, et al.. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol, 2003, 171(3): 1232-1239